Aastrom Biosciences, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Private equity placement of 2.8 mil. shares of common stock raises $6 mil. to support clinical trial programs for the AastromReplicell cell production system and to expand operations. The financing is the second for the Ann Arbor, Michigan-based firm this year, with a total of about $12 mil. raised so far. The funds "have allowed us to resume our U.S. clinical trial programs and to initiate expanded operations," Aastrom says. "Additionally, we are now in position to resume pilot European marketing of the AastromReplicell system and to pursue application of our products and technologies into new therapy opportunities"
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.